JP2017514871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514871A5 JP2017514871A5 JP2016566909A JP2016566909A JP2017514871A5 JP 2017514871 A5 JP2017514871 A5 JP 2017514871A5 JP 2016566909 A JP2016566909 A JP 2016566909A JP 2016566909 A JP2016566909 A JP 2016566909A JP 2017514871 A5 JP2017514871 A5 JP 2017514871A5
- Authority
- JP
- Japan
- Prior art keywords
- glyx
- administering
- patient
- effective amount
- cognitive impairment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- GIBQQARAXHVEGD-BSOLPCOYSA-N rapastinel Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CCC1 GIBQQARAXHVEGD-BSOLPCOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461989183P | 2014-05-06 | 2014-05-06 | |
| US61/989,183 | 2014-05-06 | ||
| PCT/US2015/029477 WO2015171770A1 (en) | 2014-05-06 | 2015-05-06 | Combinations of nmdar modulating compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020083060A Division JP2020138973A (ja) | 2014-05-06 | 2020-05-11 | Ｎｍｄａｒ調節化合物の組合せ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017514871A JP2017514871A (ja) | 2017-06-08 |
| JP2017514871A5 true JP2017514871A5 (OSRAM) | 2018-06-14 |
Family
ID=54392956
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016566909A Pending JP2017514871A (ja) | 2014-05-06 | 2015-05-06 | Ｎｍｄａｒ調節化合物の組合せ |
| JP2020083060A Pending JP2020138973A (ja) | 2014-05-06 | 2020-05-11 | Ｎｍｄａｒ調節化合物の組合せ |
| JP2022116942A Pending JP2022159322A (ja) | 2014-05-06 | 2022-07-22 | Ｎｍｄａｒ調節化合物の組合せ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020083060A Pending JP2020138973A (ja) | 2014-05-06 | 2020-05-11 | Ｎｍｄａｒ調節化合物の組合せ |
| JP2022116942A Pending JP2022159322A (ja) | 2014-05-06 | 2022-07-22 | Ｎｍｄａｒ調節化合物の組合せ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20170072005A1 (OSRAM) |
| EP (1) | EP3139943A4 (OSRAM) |
| JP (3) | JP2017514871A (OSRAM) |
| KR (2) | KR20220102662A (OSRAM) |
| CN (1) | CN106659762A (OSRAM) |
| AU (1) | AU2015256075B2 (OSRAM) |
| BR (1) | BR112016025910A8 (OSRAM) |
| CA (1) | CA2947976A1 (OSRAM) |
| MX (1) | MX2016014581A (OSRAM) |
| RU (1) | RU2721948C2 (OSRAM) |
| WO (1) | WO2015171770A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017002775A (es) | 2014-09-15 | 2017-08-10 | Rugen Holdings (Cayman) Ltd | Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b. |
| US20180271869A1 (en) * | 2014-09-22 | 2018-09-27 | Jie Liu | Treatment of anxiety disorders and autism spectrum disorders |
| US10221182B2 (en) | 2015-02-04 | 2019-03-05 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists |
| EP3297619B1 (en) * | 2015-05-22 | 2022-07-06 | Vistagen Therapeutics, Inc. | Therapeutic uses of l-4-chlorokynurenine |
| CN107849010B (zh) | 2015-06-01 | 2021-11-09 | 卢郡控股(开曼)有限公司 | 作为nr2b nmda受体拮抗剂的3,3‐二氟哌啶氨基甲酸酯杂环化合物 |
| US20180303793A1 (en) * | 2015-10-16 | 2018-10-25 | Scythian Biosciences Inc. | Methods and compositions for treating traumatic brain injury |
| CA3002070A1 (en) * | 2015-10-16 | 2017-04-20 | Northwestern University | Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder |
| TWI648049B (zh) * | 2016-05-25 | 2019-01-21 | National Health Research Institutes | 用於減低ｋ他命之致精神病狀副作用及成癮疾患的方法與組成物 |
| US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| CN107550907A (zh) * | 2017-08-29 | 2018-01-09 | 昆明医科大学 | 治疗精神分裂症的药物及验证药物的动物模型构建方法 |
| KR20200096946A (ko) * | 2017-12-05 | 2020-08-14 | 노렉스, 인크. | 조합된 치료(수면 및 cns 장애)용 nmda 수용체 조절자(라파스티넬) 조합물 |
| PT3505157T (pt) | 2017-12-29 | 2022-02-18 | Celon Pharma Sa | Composição de cetamina em pó seco para administração pulmonar em depressão resistente ao tratamento |
| CN110343050B (zh) * | 2018-04-04 | 2021-09-24 | 上海键合医药科技有限公司 | 芳香类化合物及其制备方法和用途 |
| CN109223785A (zh) * | 2018-10-29 | 2019-01-18 | 中国药科大学 | 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用 |
| WO2020146878A1 (en) * | 2019-01-11 | 2020-07-16 | Naurex Inc. | Salt and crystalline forms of rapastinel |
| JP7433331B2 (ja) * | 2019-02-14 | 2024-02-19 | アルジャーノン・ファーマスーティカルズ・インコーポレイテッド | 特発性肺線維症を治療するための組成物及び方法 |
| US12472170B2 (en) | 2019-10-28 | 2025-11-18 | Seyltx, Inc. | Use of glutamate 2B receptor antagonists and sigma receptor agonists as antitussives |
| CN113234036B (zh) * | 2021-05-12 | 2023-07-14 | 斯莱普泰(上海)生物医药科技有限公司 | Nmda受体拮抗剂及其用途 |
| KR20230056971A (ko) * | 2021-10-21 | 2023-04-28 | 삼육대학교산학협력단 | 신규 케타민 유도체를 포함하는 우울증 예방 또는 치료용 약학적 조성물 |
| US20240100061A1 (en) | 2022-09-14 | 2024-03-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions of Iboga Alkaloids and Methods of Treatment |
| WO2025065271A1 (en) * | 2023-09-26 | 2025-04-03 | Liangzhu Laboratory | Methods and devices for treating depression |
| WO2025124571A1 (zh) * | 2023-12-14 | 2025-06-19 | 斯莱普泰(上海)生物医药科技有限公司 | Nmda受体拮抗剂及其用途 |
| CN119174765A (zh) * | 2024-09-04 | 2024-12-24 | 复旦大学附属中山医院 | Gsdme蛋白的小分子抑制剂在肿瘤及其免疫治疗中的作用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5597809A (en) * | 1994-06-23 | 1997-01-28 | Massachusetts Eye & Ear Infirmary | Treatment of optic neuritis |
| CA2528622C (en) * | 2003-05-27 | 2010-08-03 | Forest Laboratories, Inc. | Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders |
| GB0523998D0 (en) * | 2005-11-25 | 2006-01-04 | Merck Sharp & Dohme | Therapeutic agents |
| US20090275597A1 (en) * | 2008-05-02 | 2009-11-05 | Forest Laboratories Holdings Limited | Methods of treating cns disorders |
| MX2010014172A (es) * | 2008-07-03 | 2011-02-22 | Amira Pharmaceuticals Inc | Antagonistas de receptores de prostaglandina d2. |
| JP2012514006A (ja) * | 2008-12-29 | 2012-06-21 | バンダービルト ユニバーシティ | ３．１．０二環式ＧｌｙＴ１阻害剤ならびにその作製および使用の方法 |
| US8951968B2 (en) * | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| EP2582366B1 (en) * | 2010-06-15 | 2015-10-28 | Grünenthal GmbH | Pharmaceutical combination for the treatment of pain |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| MX2014010939A (es) * | 2012-03-12 | 2014-11-13 | Janssen Pharmaceutica Nv | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento. |
-
2015
- 2015-05-06 RU RU2016146714A patent/RU2721948C2/ru active
- 2015-05-06 CN CN201580031430.2A patent/CN106659762A/zh active Pending
- 2015-05-06 JP JP2016566909A patent/JP2017514871A/ja active Pending
- 2015-05-06 KR KR1020227022906A patent/KR20220102662A/ko not_active Ceased
- 2015-05-06 US US15/309,390 patent/US20170072005A1/en not_active Abandoned
- 2015-05-06 KR KR1020167034031A patent/KR20170013890A/ko not_active Ceased
- 2015-05-06 AU AU2015256075A patent/AU2015256075B2/en not_active Ceased
- 2015-05-06 EP EP15789211.8A patent/EP3139943A4/en not_active Withdrawn
- 2015-05-06 BR BR112016025910A patent/BR112016025910A8/pt not_active Application Discontinuation
- 2015-05-06 WO PCT/US2015/029477 patent/WO2015171770A1/en not_active Ceased
- 2015-05-06 CA CA2947976A patent/CA2947976A1/en not_active Abandoned
- 2015-05-06 MX MX2016014581A patent/MX2016014581A/es unknown
-
2020
- 2020-05-11 JP JP2020083060A patent/JP2020138973A/ja active Pending
-
2022
- 2022-07-22 JP JP2022116942A patent/JP2022159322A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514871A5 (OSRAM) | ||
| KR20220012274A9 (ko) | 플루오린 함유 화합물 및 이의 항암 의학적 용도 | |
| MA52257A (fr) | Compositions pharmaceutiques comprenant blautia et leur administration orale | |
| EP3558424A4 (en) | DRUG DELIVERY SYSTEMS AND METHODS | |
| EP3399972A4 (en) | LOW-DOSED THERAPEUTIC TREATMENT | |
| IL254207B (en) | Oral care compositions and methods of use | |
| JP2016518337A5 (OSRAM) | ||
| EP3681479A4 (en) | METHOD OF ADMINISTRATION AND TREATMENT | |
| HUE053309T2 (hu) | Új sók és gyógyászati készítmények gyulladásos betegségek kezelésére | |
| HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
| JP2015503422A5 (OSRAM) | ||
| HUE058731T2 (hu) | Gyógyászati készítmények, kezelési eljárások és ezek alkalmazásai | |
| IL260955A (en) | A mini tablet for oral administration containing sacubitril and valsartan for the treatment of heart failure | |
| HUE060496T2 (hu) | Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére | |
| EP3253451A4 (en) | Diagnosis and treatment of chronic pain | |
| PT4335517T (pt) | Administração e dosagem de diaminofenotiazinas | |
| HUE071358T2 (hu) | Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk | |
| JP2015522522A5 (OSRAM) | ||
| MA46621A (fr) | Traitements combinés comprenant l'administration d'imidazopyrazinones | |
| MX2017003513A (es) | Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia. | |
| HUE058354T2 (hu) | Hidrofil bevonattal rendelkezõ higiénikus orvosi eszközök és eljárások azok kialakítására | |
| HUE062784T2 (hu) | Indolinon vegyületek és alkalmazásuk fibrotikus betegségek kezelésében | |
| IL287704A (en) | Use of cannabidiol in the treatment of tuberous sclerosis complex | |
| HUE066272T2 (hu) | Terápiás szer az amiotrófiás laterálszklerózisra és a kezelésre szolgáló készítmény | |
| IL264407A (en) | Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases |